GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.

​GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer. WSJ.com: US Business